Shirletta King-Davis

Learn More
INTRODUCTION In phase-3 clinical trials, the interleukin (IL-1) blocker, rilonacept (IL-1 Trap), demonstrated efficacy for gout flare prevention during initiation of urate-lowering therapy. This trial evaluated rilonacept added to a standard-of-care, indomethacin, for treatment of acute gout flares. METHODS Adults, aged 18-70 years, with gout presenting(More)
  • 1